癌症治疗的财务毒性和社会成本：不同的问题需要不同的解决方案。
Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions.
机构信息
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
出版信息
Oncologist. 2017 Feb;22(2):123-125. doi: 10.1634/theoncologist.2016-0301. Epub 2017 Feb 6.
Abstract
Control of societal costs can be addressed through clinician education, value‐based guidelines and pathways, formulary restrictions, payment reform, and government regulatory decisions but should not be imposed on patients at the point of decision‐making in the cancer clinic.
摘要
可以通过临床医生教育、基于价值的指南和途径、处方限制、支付方式改革以及政府监管决策来控制社会成本，但不应在癌症诊所的决策点强加给患者。
相似文献
1
Financial Toxicity and Societal Costs of Cancer Care: Distinct Problems Require Distinct Solutions.
Oncologist. 2017 Feb;22(2):123-125. doi: 10.1634/theoncologist.2016-0301. Epub 2017 Feb 6.
2
The financial burden of cancer care: do patients in the US know what to expect?
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):835-42. doi: 10.1586/14737167.2014.963558. Epub 2014 Oct 1.
3
New "managed access" process for Cancer Drugs Fund to go ahead, NHS England confirms.
BMJ. 2016 Feb 29;352:i1208. doi: 10.1136/bmj.i1208.
4
Financial toxicity in cancer care-Edging toward solutions.
Cancer. 2017 Apr 15;123(8):1301-1302. doi: 10.1002/cncr.30555. Epub 2017 Feb 20.
5
Financial toxicity in cancer care: Prevalence, causes, consequences, and reduction strategies.
J Surg Oncol. 2019 Jul;120(1):85-92. doi: 10.1002/jso.25374. Epub 2019 Jan 16.
6
PET/CT is a cost-effective tool against cancer: synergy supersedes singularity.
Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1749-52. doi: 10.1007/s00259-016-3414-5. Epub 2016 May 13.
7
Effective Cost Conversations: Addressing Financial Toxicity and Cost-Related Health Literacy.
Clin J Oncol Nurs. 2020 Apr 1;24(2):209-213. doi: 10.1188/20.CJON.209-213.
8
Financial Toxicity of Cancer Care: It's Time to Intervene.
J Natl Cancer Inst. 2015 Dec 11;108(5). doi: 10.1093/jnci/djv370. Print 2016 May.
9
The cost of cancer care--balancing our duties to patients versus society: are they mutually exclusive?
Oncologist. 2013;18(4):347-9. doi: 10.1634/theoncologist.2013-0078. Epub 2013 Apr 8.
10
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
Cancer. 2017 Feb 1;123(3):476-484. doi: 10.1002/cncr.30369. Epub 2016 Oct 7.
引用本文的文献
1
"I Just Had to Do What I Had to Do": Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers.
MDM Policy Pract. 2024 Oct 7;9(2):23814683241282413. doi: 10.1177/23814683241282413. eCollection 2024 Jul-Dec.
2
Experienced financial toxicity among long-term cancer survivors: results from a national cross-sectional survey.
J Cancer Surviv. 2024 Sep 3. doi: 10.1007/s11764-024-01668-2.
3
Reflections on the Financial Toxicity of Cancer: 10 Years Later.
Oncologist. 2023 Aug 3;28(8):654-656. doi: 10.1093/oncolo/oyad179.
4
Financial Toxicity of Medical Management of Heart Failure: JACC Review Topic of the Week.
J Am Coll Cardiol. 2023 May 23;81(20):2043-2055. doi: 10.1016/j.jacc.2023.03.402.
5
Impact of educational interventions on utilization patterns of anticancer agents in patients with breast cancer at the specialty oncology care setting in South India.
Perspect Clin Res. 2022 Apr-Jun;13(2):82-89. doi: 10.4103/picr.PICR_8_20. Epub 2020 Dec 9.
6
The Cancer Financial Experience (CAFÉ) study: randomized controlled trial of a financial navigation intervention to address cancer-related financial hardship.
Trials. 2022 May 13;23(1):402. doi: 10.1186/s13063-022-06344-3.
7
The socio-economic burden of cancer: An observation from the palliative care OPD.
J Family Med Prim Care. 2022 Mar;11(3):821-824. doi: 10.4103/jfmpc.jfmpc_1247_21. Epub 2022 Mar 10.
8
Mobile Application to Identify Cancer Treatment-Related Financial Assistance: Results of a Randomized Controlled Trial.
JCO Oncol Pract. 2021 Oct;17(10):e1440-e1449. doi: 10.1200/OP.20.00757. Epub 2021 Apr 2.
9
High-Value, Cost-Conscious Care Attitudes in the Graduate Medical Education Learning Environment: Various Stakeholder Attitudes That Residents Misjudge.
J Gen Intern Med. 2021 Mar;36(3):691-698. doi: 10.1007/s11606-020-06261-8. Epub 2020 Nov 2.
10
Assessing the Importance of Factors Associated with Cost-Related Nonadherence to Medication for Older US Medicare Beneficiaries.
Drugs Aging. 2019 Dec;36(12):1111-1121. doi: 10.1007/s40266-019-00715-3.
本文引用的文献
1
Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors.
Cancer. 2016 Apr 15;122(8):283-9. doi: 10.1002/cncr.29808. Epub 2016 Mar 14.
2
Physician Experience and Attitudes Toward Addressing the Cost of Cancer Care.
J Oncol Pract. 2016 Mar;12(3):e281-8, 247-8. doi: 10.1200/JOP.2015.007401. Epub 2016 Feb 16.
3
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs.
JAMA Oncol. 2015 Jul;1(4):539-40. doi: 10.1001/jamaoncol.2015.0373.
4
American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.
J Clin Oncol. 2015 Aug 10;33(23):2563-77. doi: 10.1200/JCO.2015.61.6706. Epub 2015 Jun 22.
5
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
6
Uptake and costs of hypofractionated vs conventional whole breast irradiation after breast conserving surgery in the United States, 2008-2013.
JAMA. 2014 Dec 17;312(23):2542-50. doi: 10.1001/jama.2014.16616.
7
The change from brand-name to generic aromatase inhibitors and hormone therapy adherence for early-stage breast cancer.
J Natl Cancer Inst. 2014 Oct 27;106(11). doi: 10.1093/jnci/dju319. Print 2014 Nov.
8
Patient experience and attitudes toward addressing the cost of breast cancer care.
Oncologist. 2014 Nov;19(11):1135-40. doi: 10.1634/theoncologist.2014-0117. Epub 2014 Oct 1.
9
The financial burden of cancer care: do patients in the US know what to expect?
Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):835-42. doi: 10.1586/14737167.2014.963558. Epub 2014 Oct 1.
10
Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
J Clin Oncol. 2014 Feb 1;32(4):306-11. doi: 10.1200/JCO.2013.52.9123. Epub 2013 Dec 23.
Zotero 插件